Central vascular plug-assisted portal vein embolization with absolute ethanol

Compare the efficacy and procedural efficiency of central vascular plug-assisted portal vein embolization (PVE) with absolute ethanol compared to selective PVE.

Between 2016 and 2023, patients who underwent ipsilateral percutaneous transhepatic PVE were included. Selective PVE involves serial cannulation and embolization of portal veins. Central vascular plug-assisted PVE involves deploying a vascular plug at the main portal vein with embolization. Recorded data includes patient demographics, disease diagnosis, volumetry, embolization procedure, biliary drainage, surgery, and measures of future liver remnant hypertrophy (relative hypertrophy, degree of hypertrophy, and kinetic growth rate).

The cohort comprised of 30 patients (cohort mean age 64±9 years old, females n=14) of which 17 (57%) patients underwent central vascular plug-assisted PVE. Indications for PVE were predominately (87%, 26/30) due to bile duct cancer. Volumetric changes between central vascular plug-assisted PVE and selective PVE were not different between the two groups (DH 13%±5 vs 11%±4, p=0.21; and KGR 3%/week ± 2 vs 2%/week ± 2, p=0.27, respectively). Overall procedure times were shorter for central vascular plug-assisted PVE (45±20 minutes vs 112±34 minutes; p<0.001). Two adverse events occurred in selective PVE, while none in central vascular plug-assisted PVE. There was no difference in rates of surgery or no surgery for both methods (p=0.07).

Central vascular plug-assisted PVE with absolute ethanol effectively induced FLR hypertrophy, and significantly reduced procedure times due to faster embolization and simpler technique.